ABC subfamily C member 10 (ABCC10) is a promising novel target in Hodgkins lymphoma

14^th World Cancer & Anti-Cancer Therapy Convention

November 21-23, 2016 Dubai, UAE

Ghada Mohamed Abdel Salam

Cairo University, Egypt

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Owing to the progress in its treatment, Hodgkin's lymphoma (HL) has become a potentially curable disease. However, there is a subset of HL patients, has disease that is either refractory to treatment or relapses early; outcome for these groups is particularly poor. Moreover, patients receiving combined treatment are at higher risk for second malignancies. ABCC10, also known as multidrug-resistant protein 7 (MRP7), is the tenth member of the C subfamily of the ATP-binding cassette (ABC) superfamily. ABCC10 mediates multidrug resistance (MDR) in cancer cells by preventing the intracellular accumulation of certain antitumor drugs. Our study unveiled for the first time the expression pattern and effect of ABCC10 in Hodgkin's lymphoma (HL). Results of our study showed that ABCC10 is over-expressed in most HL derived cell lines and primary HL tumor cells as compared to normal B cells. Our functional studies showed that inhibition of ABCC10 by one of inhibitor (Tariquidar) had a significant dose-dependent increase in the sensitivity of HL cells to doxorubicin. Importantly, in our study we found that overexpression of TXN was considered to be a negative prognostic factor for HL patients. We showed that there is a significant positive correlation between TXN expression level in tumor cells and tumor stage, that in turn act as a covariant, as it predicted initial response to treatment. These results indicated that ABCC10 plays a role in increasing toxicity of chemotherapy on HL cells, its overexpression affect clinical outcome, and it is a potential target in HL.

Biography :

Email: dr.ghada.elshafaee@gmail.com